Accelerating Oncology Submissions

The Oncology & Radiopharmaceutical experts you need.

MMS did a great job leading the Oncology label and provided wonderful regulatory guidance. The MMS team crushed it and the outputs were flawless.
Director, Medical Writing
Oncology Sponsor

Oncology drug development is rapidly advancing, and MMS is here to help advance your regulatory submissions with integrated and flexible services spanning across all phases of development. There remains an unmet medical need for cancer patients and continued clinical research. Early engagement with global health authorities is critical in aligning on the clinical development plan.

Navigating oncology submissions has a unique set of challenges and having the right CRO team can help you meet the demanding timelines and rapid review cycles needed in Real-Time Oncology Review (RTOR) submissions. Our flexible and adaptive team has the expertise across a range of oncology therapies to ensure this happens.

Additionally, radiopharmaceutical clinical studies require a personal approach to ensure successful submissions, and MMS can help you navigate the complex regulatory requirements by providing expertise from proof-of-concept to approval. 

Why Should Pharma Companies Be Proactive?

The following elements allow pharmaceutical companies to be properly set up for success from the onset of any oncology or radiopharmaceutical program when partnering with the right CRO:

  • Regulatory Compliance: MMS has supported countless NDAs with multiple pre-submissions waves and RFIs, serving the pharmaceutical industry as proactive strategists to comply with the current regulatory guidance from global health authorities.
  • Expedited Programs Guidance: MMS has an extensive knowledge of expedited programs, oncology submissions, and RTOR rolling reviews. We can help you gain approval by:
    – Achieving initial designations for Fast Track and Breakthrough
    – Leveraging designations to optimize clinical development
    – Preparing for the challenging timelines associated with Priority Review, rolling submissions, and Advisory Committees
    – Sharing industry best practices from our history of submissions working with partners across the pharmaceutical industry as a CRO of choice
  • Operational Excellence: MMS regulatory experts are placed on your program from start to finish to provide the continuity of services needed and to better align on messaging and program development.

Suggested For You

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development